Axsome Therapeutics (NASDAQ: AXSM) Receives "Outperform" Rating Amid Strong Drug Pipeline Progress

Font: Financial Modeling Prep  • Jul 20, 2026

• Analyst Confidence: Financial firm BMO Capital initiated "Outperform" coverage on Axsome Therapeutics, citing strong drug pipeline progress and market potential.
• Regulatory Milestones: The U.S. Food and Drug Administration (FDA) accepted Axsome Therapeutics' New Drug Application (NDA) for AXS-12, a promising narcolepsy treatment, with a PDUFA target action date of May 1, 2027.
• Pipeline Expansion & Market Outperformance: Axsome Therapeutics is expanding its clinical programs with a Phase 3 trial for ADHD treatment, contributing to its impressive 30.1% year-to-date stock rally, significantly outpacing the broader industry.

On July 20, 2026, financial firm BMO Capital initiated coverage on Axsome Therapeutics (NASDAQ: AXSM), giving it an "Outperform" rating when the stock price was $221.64. Axsome Therapeutics is a biopharmaceutical company that focuses on developing new medicines for central nervous system disorders, which affect the brain and spinal cord.

The positive rating follows significant progress in the company's drug pipeline. As highlighted by GlobeNewswire, the U.S. Food and Drug Administration (FDA) accepted Axsome Therapeutics' New Drug Application (NDA) for AXS-12. An NDA is a formal step a company takes to ask the FDA to approve a new drug for sale and marketing.

The drug, AXS-12, is intended to treat cataplexy in patients with narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027. This PDUFA date acts as a deadline for the FDA to review the new drug's application and make a decision.

In addition to the AXS-12 development, Axsome Therapeutics is also expanding its research into other treatments. The company recently started its FOCUS-2 Phase 3 trial for solriamfetol. This study will test the drug as a potential treatment for children with attention deficit hyperactivity disorder (ADHD), showing a broadening of the company's clinical programs.

This series of positive developments is reflected in Axsome Therapeutics' stock performance. As highlighted by Zacks, shares of Axsome Therapeutics have rallied 30.1% year-to-date. This performance significantly outpaces the broader industry's average increase of 1.9% over the same period, supporting the new "Outperform" grade from analysts.